Americans are spending way too much on health care, and getting far too little in return. Together we can bring down the cost of prescription drugs, prevent surprise medical bills, get providers to rein in skyrocketing costs, and more.
The Latest on Health care
Looking ahead: protecting the climate, nature and consumers in 2024
PIRG builds on campaign to improve hospital price transparency to drive down high prices in health care
Sign up for a quick primer on medical bill protections
Public’s right to challenge weak patents for Rx drugs is at risk.
Medical Bills: Everything you need to know about your rights.
What You Can Do
Tell your U.S. senators: Pass health care price transparency
Tell your US Representative: Lower Costs, More Transparency
Tell your governor: End unjustified facility fees
A bad deal: Why you don’t want (medical credit) cards in your hand
Patient protections needed from medical credit cards
Did your insurance deny your health care claim? How to appeal.
The Cost of Prescription Drug Patent Abuse
Year in review: PIRG’s 2023 highlights
PIRG, its state groups celebrate national, state, local victories for the public interest
Release: New consumer guide warns against use of ‘medical credit cards’
Payment method can worsen financial burden on patients already struggling to pay for health care
Facility fees are driving up the prices of doctor visits.
Hospital facility fees are tacked onto bills for doctor visits. But why?
Was your health insurance claim denied by an algorithm? Thousands are.
Did a doctor or an AI-bot deny your health insurance claim? What you need to know.
SCOTUS action will limit generic drug competition
U.S. Supreme Court on Monday declined to review a federal circuit court decision that imperils a critical method that many generic drug makers use to win approval. The court denied a petition of certiorari in Teva Pharmaceuticals USA, Inc. V GlaxoSmithKline LLC, Et. Al., allowing the divided lower court's decision to stand. This action can have dramatically limit competition from lower-priced generic and biosimilar medicines.